ATOS Profile
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative treatments for oncology and infectious diseases. Based in Seattle, Washington, the company is focused on advancing its pipeline of therapeutic candidates through rigorous clinical development. Atossa’s primary research aims to address significant unmet medical needs, particularly in the fields of breast cancer and COVID-19.
The company's lead program, Endoxifen, is an active metabolite of the widely used breast cancer medication tamoxifen. Endoxifen is currently undergoing Phase II clinical trials, targeting both the treatment and prevention of breast cancer. This program represents a significant advancement in personalized cancer therapy, with the potential to improve outcomes for patients through more effective and tailored treatment approaches. In addition to Endoxifen, Atossa is developing several promising therapies for COVID-19, including AT-H201, an inhalation therapy designed to enhance lung function in severely ill and hospitalized patients, and AT-301, a proprietary nasal administration drug aimed at treating patients diagnosed with COVID-19.
Atossa Therapeutics is also advancing its research in immunotherapy and chimeric antigen receptor (CAR) therapy, focusing on innovative treatments for breast cancer. These cutting-edge approaches have the potential to revolutionize cancer care by harnessing the power of the immune system to target and destroy cancer cells more effectively. The company has established a research agreement with Dana-Farber Cancer Institute, Inc. to support the development of cytokine-coated nanoparticles as a novel treatment for breast cancer, underscoring its commitment to collaborative and high-impact research.
Founded in 2008 and originally known as Atossa Genetics Inc., the company rebranded as Atossa Therapeutics, Inc. in January 2020 to better reflect its expanded focus on therapeutic development. Atossa's strategic emphasis on developing transformative therapies for cancer and infectious diseases positions it as a key player in advancing medical science and improving patient outcomes. With a robust pipeline and strategic collaborations, Atossa continues to drive innovation and progress in the biopharmaceutical industry.
|
